Notice NOT-AT-19-010 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-068 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-013 from the NIH Guide for Grants and Contracts

Notice NOT-DC-19-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-19-035 from the NIH Guide for Grants and Contracts. The Center to Reduce Cancer Health Disparities (CRCHD) of the National Cancer Institute (NCI), in partnership with the NCI Office of Cancer Centers (OCC), announces this opportunity to compete for administrative supplements to Cancer Center Support Grants (CCSGs; P30s) for NCI-designated Cancer Centers (CCs) to each recruit a Community Health Educator (CHE). The purpose of this administrative supplement funding opportunity is to support a strengthening of community outreach capacity by working through the National Outreach Network (NON). It is expected that NON CHEs, located at NCI-designated CCs, will enhance the development and dissemination of culturally appropriate, evidence-based cancer information to members of underserved communities including rural and racial/ethnic populations (e.g., African American/Black, American Indian/Alaska Native, Asian, Hispanic/Latino, Native Hawaiian/Other Pacific Islander) in a way that is tailored to their specific needs.

Notice NOT-TR-19-009 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-19-034 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to solicit applications from small business concerns (SBCs) to initiate early research ultimately leading to the commercialization of understudied proteins identified in the "Illuminating the Druggable Genome" project (IDG; https://commonfund.nih.gov/idg/index ). The purpose of the IDG is to reveal the function of selected understudied proteins in the druggable genome. Organized as a consortium, the project consists of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), a Resource Dissemination and Outreach Center (RDOC) and projects developing Cutting Edge Informatics Tools (CEITs). Small businesses are expected to complement the IDG Centers by proposing projects to commercially validate reagents, data or experimental approaches. Projects could range from early proof-of-concept demonstration and assay development/validation to the initiation of preclinical drug discovery projects.

Funding Opportunity PA-19-033 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to solicit applications from small business concerns (SBCs) to initiate early research ultimately leading to the commercialization of understudied proteins identified in the "Illuminating the Druggable Genome" project (IDG; https://commonfund.nih.gov/idg/index ). The purpose of the IDG is to reveal the function of selected understudied proteins in the druggable genome. Organized as a consortium, the project consists of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), a Resource Dissemination and Outreach Center (RDOC) and projects developing Cutting Edge Informatics Tools (CEITs). Small businesses are expected to complement the IDG Centers by proposing projects to commercially validate reagents, data or experimental approaches. Projects could range from early proof-of-concept demonstration and assay development/validation to the initiation of preclinical drug discovery projects.

Notice NOT-TR-19-008 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-032 from the NIH Guide for Grants and Contracts. NLM Grants for Scholarly Works in Biomedicine and Health are awarded for the preparation of book-length manuscripts and other works of academic and/or public health policy value to U.S. health professionals, public health officials, biomedical researchers and historians of the health sciences.

Notice NOT-DE-18-023 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-FD-20-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support clinical studies of products that address unmet needs in rare diseases or conditions or provide highly significant improvements in treatment or diagnosis. Through the support of efficient and innovative clinical studies evaluating safety and/or effectiveness, FDA expects to increase the number of treatments for rare diseases with an unmet medical need and support studies that will either result in market approval of these products or substantially contribute to the essential data needed for medical product development that will ultimately meet the needs of rare disease patients.

Notice NOT-CA-19-005 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-19-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support pilot studies aimed to establish molecular, anatomical, and functional cell and circuit census data from selected brain regions of young and old C57BL/6J mice. This will complement and build on current BRAIN Initiative efforts while informing a design for a comprehensive characterization of cells and circuits in the brain across the lifespan, including the generation of a comprehensive 3D brain cell reference atlas of the aging mouse brain.

Notice NOT-HL-18-659 from the NIH Guide for Grants and Contracts

Notice NOT-HL-18-660 from the NIH Guide for Grants and Contracts

Notice NOT-TW-18-005 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-005 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-006 from the NIH Guide for Grants and Contracts

Notice NOT-DA-19-004 from the NIH Guide for Grants and Contracts